Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + GEMOX in Advanced Biliary Tract Tumors
NCT04191343Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2019
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in biliary tract cancer (BTC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04191343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191343.